Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May;12(3):157-64.
doi: 10.1007/s11908-010-0102-7.

Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development

Affiliations

Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development

Annelies Wilder-Smith et al. Curr Infect Dis Rep. 2010 May.

Abstract

Dengue virus is the most widespread geographically of the arboviruses and a major public health threat in the tropics and subtropics. Scientific advances in recent years have provided new insights about the pathogenesis of more severe disease and novel approaches into the development of antiviral compounds and dengue vaccines. Phylogenetic studies show an association between specific subtypes (within serotypes) and severity of dengue. The lack of association between maternal antibodies and development of severe dengue in infants in a recent study has called for the rethinking or refinement of the current antibody-dependent enhancement theory of dengue hemorrhagic syndrome in infancy. Such studies should stimulate new directions of research into mechanisms responsible for the development of severe dengue. The life cycle of dengue virus readily shows that virus entry and replication can be targeted by small molecules. Advances in a mouse model (AG 129 mice) have made it easier to test such antiviral compounds. The efforts to find specific dengue inhibitors are intensifying and the tools to evaluate the efficacy of new drugs are now in place for rapid translation into trials in humans. Furthermore, several dengue vaccine candidates are in development, of which the chimeric dengue/yellow fever vaccine has now entered phase 3 trials. Until the availability of a licensed vaccine, disease surveillance and vector population control remain the mainstay of dengue prevention.

PubMed Disclaimer

References

    1. Hum Vaccin. 2006 Mar-Apr;2(2):60-7 - PubMed
    1. Ann N Y Acad Sci. 2009 Sep;1171 Suppl 1:E12-23 - PubMed
    1. Annu Rev Entomol. 2008;53:273-91 - PubMed
    1. Antiviral Res. 2010 Mar;85(3):450-62 - PubMed
    1. J Med Entomol. 1998 Sep;35(5):646-52 - PubMed

LinkOut - more resources